Maintenance of androgen receptor inactivation by S-Nitrosylation

Cancer Research

Volumn 73, Issue 22, 2013, Pages 6690-6699

  Qin, Yu ^a   Dey, Anindya ^a   Purayil, Hamsa Thayele ^a   Daaka, Yehia ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DNA; GONADORELIN; HEAT SHOCK PROTEIN 90; NITRIC OXIDE; NITRIC OXIDE DONOR; S NITROSOGLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA BINDING; DNA RESPONSIVE ELEMENT; GEL MOBILITY SHIFT ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL PROLIFERATION; HEK293 CELLS; HUMANS; MALE; MICE; MICE, SCID; NITRIC OXIDE; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; S-NITROSOTHIOLS; SULFHYDRYL COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 84888364915     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1042     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-8.
3. Shapiro D, Tareen B. Current and emerging treatments in the management of castration-resistant prostate cancer. Expert Rev Anticancer Ther 2012;12:951-64.
4. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011;17:1649-57.
5. Autio KA, Scher HI, Morris MJ. Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Curr Treat Options Oncol 2012;13:174-88.
6. Han GZ, Buchanan G, Ittmann M, Harris JM, Yu XQ, DeMayo FJ, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A 2005;102:1151-6.
7. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
8. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29:3651-8.
9. Heinlein CA, Chang C. Androgen receptor coregulators: an overview. Endocr Rev 2002;23:175-200.
10. Heemers HV, Tindall DJ. Androgen receptor coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007;28:778-808.
11. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, et al. Androgen receptor phosphorylation: regulation and identification of the phosphorylation sites. J Biol Chem 2002;277:29304-14.
12. Fu MF, Wang CG, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 2000;275:20853-60.
13. Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie ZZ, Messias NC, et al. Identification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci U S A 2009;106:9379-84.
14. Wang Z, Humphrey C, Frilot N, Wang G, Nie Z, Moniri NH, et al. Dynamin2- and endothelial nitric oxide synthase-regulated invasion of bladder epithelial cells by uropathogenic Escherichia coli. J Cell Biol 2011;192:101-10.
15. Wang G, Moniri NH, Ozawa K, Stamler JS, Daaka Y. Nitric oxide regulates endocytosis by S-nitrosylation of dynamin. Proc Natl Acad Sci U S A 2006;103:1295-300.
16. Lancaster JR, Xie KP. Tumors face NO problems? Cancer Res 2006;66:6459-62.
17. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006;8:1329-37.
18. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001;29:25-8.
19. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, et al. Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 2009;119:1093-108.
20. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV, et al. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 2007;26:1875-84.
21. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trend Mol Med 2009;15:391-404.
22. Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, et al. Regulation of βAdrenergic receptor signaling by S-nitrosylation of G protein-coupled receptor kinase 2. Cell 2007;129:511-22.
23. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 2001;3:193-7.
24. Uehara T, Nakamura T, Yao DD, Shi ZQ, Gu ZZ, Ma YL, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006;441:513-7.
25. Jaffrey SR, SnyderSH. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001;2001:pl1.
26. Matsumoto A, Gow AJ. Membrane transfer of S-nitrosothiols. Nitric Oxide 2011;25:102-7.
27. Hao G, Derakhshan B, Shi L, Campagne F, Gross SS. SNOSID, a proteomic method for identification of cysteine S-nitrosylation sites in complex protein mixtures. Proc Natl Acad Sci U S A 2006;103:1012-7.
28. FosterMW,Yang ZH, Gooden DM, Thompson JW, Ball CH, Turner ME, et al. Proteomic characterization of the cellular response to nitrosative stress mediated by S-nitrosoglutathione reductase inhibition. J Proteome Res 2012;11:2480-91.
29. Kroncke KD. Zinc finger proteins as molecular targets for nitric oxide-mediated gene regulation. Antioxid Redox Signal 2001;3:565-75.
30. Garban HJ, Marquez-Garban DC, Pietras RJ, Ignarro LJ. Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci U S A 2005;102:2632-6.
31. Marshall HE, Stamler JS. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 2001;40:1688-93.
32. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, et al. Dynamic activation of endothelial nitric oxide synthase by HSP90. Nature 1998;392:821-4.
33. Martinez-Ruiz A, Villanueva L, de Orduna CG, Lopez-Ferrer D, Higueras MA, Tarin C, et al. S-nitrosylation of HSP90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci U S A 2005;102:8525-30.
34. Kornberg MD, Sen N, Hara MR, Juluri KR, Nguyen JVK, Snowman AM, et al. GAPDH mediates nitrosylation of nuclear proteins. Nat Cell Biol 2010;12:1094-100.
35. Nakamura T, Wang L, Wong CCL, Scott FL, Eckelman BP, Han XM, et al. Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol Cell 2010;39:184-95.
36. Stamler JS, Hess DT. Nascent nitrosylases. Nat Cell Biol 2010;12:1024-6.
37. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
38. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase I-II study. Lancet 2010;375:1437-46.
39. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011;18:R183-96.
40. Sun SH, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
41. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, et al. Regression of castrate-recurrent prostate cancer by a small molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17:535-46.
42. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
43. Zhang XT, Morrissey C, Sun SH, Ketchandji M, Nelson PS, True LD, et al. Androgen receptor variants occur frequently in castration-resistant prostate cancer metastases. PLos ONE 2011;6:e27970.
44. Kroncke KD, Fehsel K, Schmidt T, Zenke FT, Dasting I, Wesener JR, et al. Nitric oxide destroys zinc sulfur clusters inducing zinc release from metallothionein and inhibition of the zinc finger-type yeast transcription activator LAC9. Biochem Biophys Res Commun 1994;200:1105-10
45. Siemens DR, Heaton JPW, Adams MA, Kawakami J, Graham CH. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009;74:878-83.